Omixon is pleased to announce the signature of a Distribution Agreement with SeqGene, based in Taipei City, Taiwan. The agreement is effective 1st October, 2014.
SeqGene is a molecular biology company. They specialize in next generation sequencing (NGS)-based services for oncology studies and HLA typing. The company is a recent spin off of the National University of Taiwan and its management team has several years of commercial experience and track record in the NGS field.
SeqGene’s sequencing platform is based on Illumina’s MiSeq and the company has established close contacts with blood banks and stem cells centres, as well as international collaborations.
There are currently interesting opportunities in the HLA field in Taiwan. Alongside the traditional activities related to transplantation, there are a number of ongoing genetic screenings supported by the Taiwanese National Health Service. One example is the nationwide screening for HLA-B*1502, which is a known drug hypersensitivity factor.
Building on this molecular biology expertise, SeqGene has now agreed a partnership with Omixon for the exclusive distribution of Omixon’s HLA typing software in Taiwan.
For more informations about our distributors, click here…